Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jemma Hazan

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Prevention of Alzheimer'S Disease|May 7, 2026
Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE<sub>4</sub> heterozygotes and non-carriersJemma Hazan, Kathy Y Liu, Robert Howard
The Journal of Prevention of Alzheimer'S Disease|February 21, 2026
Long-term extension data do not robustly support clinical disease course modification with donanemabJemma Hazan, Kathy Y Liu, Robert Howard
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 1, 2026
What should convince a clinician of disease modification in Alzheimer's disease clinical trials?Jemma Hazan, Kathy Y Liu, Robert Howard
International Journal of Geriatric Psychiatry|July 2, 2026
England's Dementia Diagnosis Landscape: Strengths, Limitations, and Future DirectionsJemma Hazan, Robert Howard, Jeremy D Isaacs
BMJ Open Quality|March 10, 2022
Improving the handover process in a psychiatry liaison settingKirtana Vallabhaneni, Jemma Hazan, Lucinda Donaldson, et al.
Journal of Alzheimer'S Disease : JAD|May 30, 2023
Advancing Diagnostic Certainty in Alzheimer's Disease: A Synthesis of the Diagnostic ProcessJemma Hazan, Kathy Y Liu, Nick Fox, et al.
International Journal of Geriatric Psychiatry|January 8, 2022
Practical application of Alzheimer's Disease Neuroimaging Initiative plasma P-tau181 reference data to support diagnosis of Alzheimer's diseaseJemma Hazan, Duncan Alston, Nick C Fox, et al.
Brain Communications|December 13, 2023
Online clinical tools to support the use of new plasma biomarker diagnostic technology in the assessment of Alzheimer's disease: a narrative reviewJemma Hazan, Kathy Y Liu, Nick C Fox, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 27, 2025
Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practiceJemma Hazan, Kathy Y Liu, Jeremy D Isaacs, et al.
Aging & Mental Health|October 16, 2024
Dementia diagnosis rates and the impact of ethnicity, rurality and deprivationJemma Hazan, Kathy Y Liu, Jeremy D Isaacs, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Prevention of Alzheimer'S Disease|May 7, 2026
Clarity AD open-label extension data do not robustly confirm disease course modification by lecanemab in ApoE<sub>4</sub> heterozygotes and non-carriersJemma Hazan, Kathy Y Liu, Robert Howard
The Journal of Prevention of Alzheimer'S Disease|February 21, 2026
Long-term extension data do not robustly support clinical disease course modification with donanemabJemma Hazan, Kathy Y Liu, Robert Howard
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 1, 2026
What should convince a clinician of disease modification in Alzheimer's disease clinical trials?Jemma Hazan, Kathy Y Liu, Robert Howard
International Journal of Geriatric Psychiatry|July 2, 2026
England's Dementia Diagnosis Landscape: Strengths, Limitations, and Future DirectionsJemma Hazan, Robert Howard, Jeremy D Isaacs
BMJ Open Quality|March 10, 2022
Improving the handover process in a psychiatry liaison settingKirtana Vallabhaneni, Jemma Hazan, Lucinda Donaldson, et al.
Journal of Alzheimer'S Disease : JAD|May 30, 2023
Advancing Diagnostic Certainty in Alzheimer's Disease: A Synthesis of the Diagnostic ProcessJemma Hazan, Kathy Y Liu, Nick Fox, et al.
International Journal of Geriatric Psychiatry|January 8, 2022
Practical application of Alzheimer's Disease Neuroimaging Initiative plasma P-tau181 reference data to support diagnosis of Alzheimer's diseaseJemma Hazan, Duncan Alston, Nick C Fox, et al.
Brain Communications|December 13, 2023
Online clinical tools to support the use of new plasma biomarker diagnostic technology in the assessment of Alzheimer's disease: a narrative reviewJemma Hazan, Kathy Y Liu, Nick C Fox, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 27, 2025
Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practiceJemma Hazan, Kathy Y Liu, Jeremy D Isaacs, et al.
Aging & Mental Health|October 16, 2024
Dementia diagnosis rates and the impact of ethnicity, rurality and deprivationJemma Hazan, Kathy Y Liu, Jeremy D Isaacs, et al.
Pageof 3